PMID- 32078191
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Sep
TI  - Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy 
      for metastatic melanoma, a cohort analysis of 189 patients.
PG  - 2096-2105
LID - 10.1111/jdv.16311 [doi]
AB  - INTRODUCTION: Cutaneous adverse events (AEs) are the most prevalent toxicity 
      under checkpoint inhibitors in clinical trials. In 'real-life' conditions of use, 
      skin toxicities under anti-PD-1 have not been described to date in a large 
      cohort. The objective of this study was to determine the clinical features of 
      skin toxicities in patients with advanced melanoma receiving anti-PD-1 therapy 
      under 'real-life' conditions of use. Secondary objectives were to evaluate the 
      characteristics of patients with skin toxicities and to analyse associated 
      extra-cutaneous toxicities, progression-free survival (PFS) and overall survival 
      (OS). PATIENTS AND METHODS: Advanced melanoma patients treated with nivolumab or 
      pembrolizumab between August 2014 and October 2017 were included. Patients lost 
      to follow-up or receiving anti-PD-1 as part of a clinical trial were excluded. 
      RESULTS: One hundred and eighty-nine patients with metastatic melanoma (with 109 
      men (57.7%) were included. Cutaneous AE occurred in 39 patients (20.6%). The 
      three most prevalent cutaneous AEs were skin eruption (macular-papular or 
      eczematous) (n = 18, 9.5%), vitiligo (n = 16; 8.5%) and isolated pruritus (n = 5, 
      2.6%). Grade 3-4 skin toxicity was diagnosed in five patients (2.6%). Atopy 
      (28.2% vs. 12.0%; P = 0.024), hypereosinophilia (20.5% vs. 8.7%; P = 0.046), 
      thyroiditis (17.9% vs. 4.7%; P = 0.011) and renal toxicity (15.4% vs. 4%; 
      P = 0.019) were significantly associated with cutaneous AE. Patients with skin 
      eruption (log-rank = 0.001), vitiligo (log-rank = 0.001) and any type of 
      cutaneous AE (log-rank < 0.001) had a better overall survival. CONCLUSIONS: 
      Cutaneous AEs are frequent and often manageable toxicity and were a predictor of 
      tumour response in melanoma patients under anti-PD-1 therapy in this cohort.
CI  - (c) 2020 European Academy of Dermatology and Venereology.
FAU - Bottlaender, L
AU  - Bottlaender L
AD  - Department of Dermatology, ImmuCare, Cancer Research Centre of Lyon, Centre 
      Hospitalier Lyon Sud, Lyon 1 University, Pierre Benite Cedex, France.
FAU - Amini-Adle, M
AU  - Amini-Adle M
AUID- ORCID: 0000-0003-2366-6238
AD  - Department of Dermatology, ImmuCare, Cancer Research Centre of Lyon, Centre 
      Hospitalier Lyon Sud, Lyon 1 University, Pierre Benite Cedex, France.
FAU - Maucort-Boulch, D
AU  - Maucort-Boulch D
AD  - Service de Biostatistique - Bioinformatique, Pole Sante Publique, Hospices Civils 
      de Lyon, Lyon, France.
AD  - Universite de Lyon, Lyon, France.
AD  - Universite Lyon 1, Villeurbanne, France.
AD  - CNRS, UMR5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe 
      Biostatistique-Sante, Villeurbanne, France.
FAU - Robinson, P
AU  - Robinson P
AD  - DRCI, Hospices Civils de Lyon, Lyon, France.
FAU - Thomas, L
AU  - Thomas L
AUID- ORCID: 0000-0003-1995-2434
AD  - Department of Dermatology, ImmuCare, Cancer Research Centre of Lyon, Centre 
      Hospitalier Lyon Sud, Lyon 1 University, Pierre Benite Cedex, France.
AD  - Cancer Research Center of Lyon, Claude Bernard Lyon 1 University, Lyon, France.
FAU - Dalle, S
AU  - Dalle S
AD  - Department of Dermatology, ImmuCare, Cancer Research Centre of Lyon, Centre 
      Hospitalier Lyon Sud, Lyon 1 University, Pierre Benite Cedex, France.
AD  - Service de Biostatistique - Bioinformatique, Pole Sante Publique, Hospices Civils 
      de Lyon, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - *Antineoplastic Agents/adverse effects
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Melanoma/drug therapy
MH  - Nivolumab/adverse effects
EDAT- 2020/02/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/21 06:00
PHST- 2019/08/19 00:00 [received]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/21 06:00 [entrez]
AID - 10.1111/jdv.16311 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2096-2105. doi: 10.1111/jdv.16311. 
      Epub 2020 Apr 27.